Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISCT 2021 | The current landscape of unproven cell-based therapies

Laertis Ikonomou, PhD, University at Buffalo & The State University of New York, Buffalo, NY, provides an overview of the evolving landscape of direct-to-consumer marketing of unproven cell-based therapies, a challenge that has been facing the field of cell and gene therapies for a number of years. In line with advancements in the field in recent years, there has been an increase in the prevalence of unproven therapeutic products incorporating perinatal tissues and exosomes being offered to patients, as well as a rise in cell banking services offering the freezing of various tissues such as T-cells. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.


Laertis Ikonomou has written an expert report in a class action lawsuit filed against a business selling unproven stem cell-based interventions, and wrote the report on a pro bono basis.